APP and Alzheimer disease: In CVN-AD mice, a 120 μg dose of C16 conjugated siRNA targeting APP administered via ICV injection led to a 75% reduction of APP mRNA at 30 days, reduced associated pathological makers, and improved behavioral deficits.